ReviewInternational journal for parasitology2020
Bumped Kinase Inhibitors as therapy for apicomplexan parasitic diseases: lessons learned.
Open access · bronzeAbstract readReview
In one paragraph
Review in International journal for parasitology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 31 papers.
0numbers the graph read from it
0cells of the map it votes in
31citing papers in PubMed
4.9field-weighted citation impact, top 4% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
31 citing papers in PubMed, 48 citations in OpenAlex.
- Article
- Affino-Proteomic Analysis of Bumped Kinase Inhibitor BKI-1708 inMicroorganisms · 2026Article
- Bumped Kinase Inhibitor BKI-1708 Interferes in Cytokinesis and Drives Baryzoite Conversion in the Cyst-Forming Apicomplexan ParasitesInternational journal of molecular sciences · 2026Article
- A novel anti-Microbiology spectrum · 2026Article
- Calf Clinical Model of Cryptosporidiosis for Efficacy Evaluation of Therapeutics.Methods in molecular biology (Clifton, N.J.) · 2026Article
- BKI-1748 confers a high level of protection against ovine congenital toxoplasmosis when administered after IgM seroconversion.Frontiers in cellular and infection microbiology · 2026Article
- Anti-Cryptosporidium efficacy of BKI-1708, an inhibitor of Cryptosporidium calcium-dependent protein kinase 1.PLoS neglected tropical diseases · 2025Article
- Bumped Kinase Inhibitors Inhibit bothACS infectious diseases · 2025Article
- Treatment with BKI-1748 afterAntimicrobial agents and chemotherapy · 2025Article
- Pyridopyrimidinones as a new chemotype of calcium dependent protein kinase 1 (CDPK1) inhibitors for Cryptosporidium.Molecular and biochemical parasitology · 2024Article
- Molecular Targets of the 5-Amido-Carboxamide Bumped Kinase Inhibitor BKI-1748 inInternational journal of molecular sciences · 2024Article
- An Early Treatment With BKI-1748 Exhibits Full Protection Against Abortion and Congenital Infection in Sheep Experimentally Infected With Toxoplasma gondii.The Journal of infectious diseases · 2024Article
- Genomic and virulence analysis of in vitro cultured Cryptosporidium parvum.PLoS pathogens · 2024Article
- Anti-Cryptosporidial Drug-Discovery Challenges and Existing Therapeutic Avenues: A "One-Health" Concern.Life (Basel, Switzerland) · 2024Review
- Single and combination treatment of Toxoplasma gondii infections with a bumped kinase inhibitor and artemisone in vitro and with artemiside in experimentally infected mice.Experimental parasitology · 2023Article
- Structure-Activity relationships of replacements for the triazolopyridazine of Anti-Cryptosporidium lead SLU-2633.Bioorganic & medicinal chemistry · 2023Article
- Comparison of Toxicities among Different Bumped Kinase Inhibitor Analogs for Treatment of Cryptosporidiosis.Antimicrobial agents and chemotherapy · 2023Article
- The Marine Compound Tartrolon E Targets the Asexual and Early Sexual Stages ofMicroorganisms · 2022Article
- High-Throughput Screening of a Marine Compound Library Identifies Anti-Marine drugs · 2022Article
- Common Molecular Targets of a Quinolone Based Bumped Kinase Inhibitor inInternational journal of molecular sciences · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
26 authors at 8 institutions in 3 countries.
Ryan ChoiDepartment of Medicine, Division of Allergy and Infectious Diseases, Center for Emerging and Reemerging Infectious Diseases (CERID), University of Washington, Seattle, WA 98109, USA.
Matthew A HulversonDepartment of Medicine, Division of Allergy and Infectious Diseases, Center for Emerging and Reemerging Infectious Diseases (CERID), University of Washington, Seattle, WA 98109, USA.
Wenlin HuangDepartment of Biochemistry, University of Washington, Seattle, WA 98195, USA.
Rama S R VidadalaDepartment of Chemistry, University of Washington, Seattle, WA 98195, USA.
Grant R WhitmanDepartment of Medicine, Division of Allergy and Infectious Diseases, Center for Emerging and Reemerging Infectious Diseases (CERID), University of Washington, Seattle, WA 98109, USA.
Lynn K BarrettDepartment of Medicine, Division of Allergy and Infectious Diseases, Center for Emerging and Reemerging Infectious Diseases (CERID), University of Washington, Seattle, WA 98109, USA.
Deborah A SchaeferSchool of Animal and Comparative Biomedical Sciences, College of Agriculture and Life Sciences, University of Arizona, Tucson, AZ 85721, USA.
Dana P BetzerSchool of Animal and Comparative Biomedical Sciences, College of Agriculture and Life Sciences, University of Arizona, Tucson, AZ 85721, USA.
Michael W RiggsSchool of Animal and Comparative Biomedical Sciences, College of Agriculture and Life Sciences, University of Arizona, Tucson, AZ 85721, USA.
J Stone DoggettVA Portland Health Care System, Portland, OR 97239, USA.
Andrew HemphillInstitute of Parasitology, Vetsuisse Faculty, University of Bern, Länggass-Strasse 122, CH-3012 Bern, Switzerland.
Luis Miguel Ortega-MoraSALUVET, Animal Health Department, Faulty of Veterinary Sciences, Complutense University of Madrid, Madrid, Spain.
Molly C McCloskeyDepartment of Medicine, Division of Allergy and Infectious Diseases, Center for Emerging and Reemerging Infectious Diseases (CERID), University of Washington, Seattle, WA 98109, USA.
Samuel L M ArnoldDepartment of Medicine, Division of Allergy and Infectious Diseases, Center for Emerging and Reemerging Infectious Diseases (CERID), University of Washington, Seattle, WA 98109, USA.
Robert C HackmanFred Hutchinson Cancer Research Center, Seattle, WA 98109, USA; Department of Pathology, University of Washington, Seattle, WA 98195, USA; Department of Laboratory Medicine, University of Washington, Seattle, WA 98195, USA.
Kennan C MarshResearch and Development, AbbVie, Inc, North Chicago, IL 60064, USA.
James J LynchResearch and Development, AbbVie, Inc, North Chicago, IL 60064, USA.
Gail M FreibergResearch and Development, AbbVie, Inc, North Chicago, IL 60064, USA.
Bruce E LeroyResearch and Development, AbbVie, Inc, North Chicago, IL 60064, USA.
Dale J KempfResearch and Development, AbbVie, Inc, North Chicago, IL 60064, USA.
Robert K M ChoyPATH, San Francisco, CA 94108 USA.
Eugenio L de HostosPATH, San Francisco, CA 94108 USA.
Dustin J MalyDepartment of Chemistry, University of Washington, Seattle, WA 98195, USA.
Erkang FanDepartment of Biochemistry, University of Washington, Seattle, WA 98195, USA.
Kayode K OjoDepartment of Medicine, Division of Allergy and Infectious Diseases, Center for Emerging and Reemerging Infectious Diseases (CERID), University of Washington, Seattle, WA 98109, USA.
Wesley C Van VoorhisDepartment of Medicine, Division of Allergy and Infectious Diseases, Center for Emerging and Reemerging Infectious Diseases (CERID), University of Washington, Seattle, WA 98109, USA. Electronic address: wesley@uw.edu.
University of Washington · USAbbVie (United States) · USUniversity of Arizona · USProgram for Appropriate Technology in Health · USFred Hutch Cancer Center · USUniversidad Complutense de Madrid · ESUniversity of Bern · CHVA Portland Health Care System · US
Funding
Bumped Kinase Inhibitors: Novel Therapeutics for Cryptosporidiosis&ToxoplasmosisR01AI111341 · NIAID · UNIVERSITY OF WASHINGTON · PI VAN VOORHIS, WESLEY C · 2014 to 2018
$6.4MCalcium Dependent Protein Kinase 1 as a drug target for T. gondii and C. parvumR01AI089441 · NIAID · UNIVERSITY OF WASHINGTON · PI MERRITT, ETHAN A, PARSONS, MARILYN · 2010 to 2014
$5.0MDual Use Therapeutics for Cryptosporidiosis, Toxoplasmosis, and NeosporosisR01HD080670 · NICHD · UNIVERSITY OF WASHINGTON · PI VAN VOORHIS, WESLEY C · 2014 to 2018
$1.9MCoformulation of bumped kinase inhibitors with Artemisinin combination therapy will stop widespread transmission of artemisinin-resistant malaria strainsR21AI123690 · NIAID · UNIVERSITY OF WASHINGTON · PI OJO, KAYODE K · 2017 to 2018
$490kBLRD VA IK2 BX002440NIAID NIH HHS R01 AI089441NIAID NIH HHS R01 AI111341NIAID NIH HHS R21 AI123690NICHD NIH HHS R01 HD080670
Abstract
Bumped Kinase Inhibitors, targeting Calcium-dependent Protein Kinase 1 in apicomplexan parasites with a glycine gatekeeper, are promising new therapeutics for apicomplexan diseases. Here we will review advances, as well as challenges and lessons learned regarding efficacy, safety, and pharmacology that have shaped our selection of pre-clinical candidates.
Indexed as
Protein Kinase InhibitorsAnimalsApicomplexaCalcium-Calmodulin-Dependent Protein KinasesCoccidiosisCryptosporidiosisCryptosporidiumHumansProtein KinasesToxoplasmaToxoplasmosisCalcium-Calmodulin-Dependent Protein KinasesProtein Kinase InhibitorsProtein KinasesApicomplexaBumped Kinase InhibitorCalcium-dependent Protein KinasesCryptosporidiumGatekeeperNeosporaSarcocystisToxoplasma
Identifiers
What OpenQuestion holds
Textmetadata
LicenceTDM
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.